We read with great interest the article by Trotta et al. evaluating the role of hydroxychloroquine (HCQ) in recurrent pericarditis (RP), as well as the accompanying commentary by Tan et al. [1,2]. The authors should be commended for providing one of the largest longitudinal real-world cohorts investigating HCQ in this setting [1]. Their findings suggest that HCQ may reduce recurrences, hospitalizations, and corticosteroid exposure in patients with idiopathic or post-cardiac injury RP [1]. We also appreciated the balanced perspective offered by Tan et al., who concluded that HCQ should currently be regarded as a steroid-sparing adjunct rather than a replacement for colchicine, corticosteroids, or anti–IL-1 biologics [2].
